Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by Gilder Gagnon Howe & Co. LLC

Gilder Gagnon Howe & Co. LLC lessened its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 13.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,928 shares of the biopharmaceutical company’s stock after selling 2,661 shares during the period. Gilder Gagnon Howe & Co. LLC’s holdings in Ultragenyx Pharmaceutical were worth $712,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of RARE. Norges Bank purchased a new stake in Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $40,463,000. Pictet Asset Management Holding SA grew its stake in Ultragenyx Pharmaceutical by 125.5% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,173,638 shares of the biopharmaceutical company’s stock worth $49,375,000 after buying an additional 653,088 shares during the period. First Trust Advisors LP grew its stake in Ultragenyx Pharmaceutical by 3,097.1% during the fourth quarter. First Trust Advisors LP now owns 544,202 shares of the biopharmaceutical company’s stock worth $22,894,000 after buying an additional 527,180 shares during the period. Fisher Asset Management LLC purchased a new stake in Ultragenyx Pharmaceutical during the fourth quarter worth approximately $11,156,000. Finally, Prudential Financial Inc. grew its stake in Ultragenyx Pharmaceutical by 659.5% during the fourth quarter. Prudential Financial Inc. now owns 272,940 shares of the biopharmaceutical company’s stock worth $11,483,000 after buying an additional 237,003 shares during the period. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Stock Up 1.2 %

Shares of Ultragenyx Pharmaceutical stock opened at $38.09 on Monday. The firm has a market cap of $3.58 billion, a P/E ratio of -6.01 and a beta of 0.61. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $29.59 and a fifty-two week high of $60.37. The business has a 50-day moving average price of $37.79 and a 200 day moving average price of $43.54.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.32) by ($0.07). The firm had revenue of $164.88 million during the quarter, compared to the consensus estimate of $163.23 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. As a group, equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CAO Theodore Alan Huizenga sold 967 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $40,710.70. Following the completion of the transaction, the chief accounting officer now directly owns 50,265 shares in the company, valued at $2,116,156.50. The trade was a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Emil D. Kakkis sold 25,000 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $42.48, for a total value of $1,062,000.00. Following the completion of the transaction, the chief executive officer now owns 2,158,985 shares of the company’s stock, valued at approximately $91,713,682.80. The trade was a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 124,643 shares of company stock valued at $5,256,268 over the last three months. 5.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have issued reports on RARE. JPMorgan Chase & Co. boosted their price objective on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an “overweight” rating in a research note on Thursday, March 27th. Cantor Fitzgerald reiterated an “overweight” rating and set a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. Canaccord Genuity Group boosted their price objective on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a research note on Tuesday, February 18th. HC Wainwright reiterated a “buy” rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Finally, Piper Sandler decreased their price objective on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating for the company in a research note on Monday, March 17th. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $92.79.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.